Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/27/2021
Summary
A Form 4 for Kim Janda, a director of Sorrento Therapeutics, Inc. [SRNE], reporting transactions on September 27, 2021 under a Rule 10b5-1 trading plan. Janda exercised stock options for 35,000 shares at $1.8 and 7,357 shares at $3.57, then sold 42,357 shares at a weighted average price of $8.0204, in transactions at prices ranging from $8.00 to $8.03, inclusive. Directly owned shares after the sale total 3,000. Footnotes state the options vested 1/12 at a time starting October 15, 2017 and December 26, 2018, and 27,643 options remain under the second grant. Henry Ji, Ph.D., signed as Attorney-in-Fact on 09/28/2021.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Sorrento Therapeutics, Inc. (SRNE), Janda Kim, transaction 09/27/2021.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-4-filed2021-09-28-0001209191-21-057957-6b75a8a58d/
, SHA-256 4483e78ad78fae8c4c2f86e5d57a20081a622eed06595209ba23d6ac92a5ba29.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Janda Kim (Last) (First) (Middle) C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Janda Kim | (Last) | (First) | (Middle) | C/O SORRENTO THERAPEUTICS, INC. | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 09/27/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 09/27/2021 | M (1) | 35,000 | A | $ 1.8 | 38,000 | D Common Stock | 09/27/2021 | M (1) | 7,357 | A | $ 3.57 | 45,357 | D Common Stock | 09/27/2021 | S (1) | 42,357 | D | $ 8.0204 (2) | 3,000 | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Stock Options | $ 1.8 | 09/27/2021 | M (1) | 35,000 | (3) | 09/15/2027 | Common Stock | 35,000 | $ 0.00 | 0 | D Stock Options | $ 3.57 | 09/27/2021 | M (1) | 7,357 | (4) | 11/26/2028 | Common Stock | 7,357 | $ 0.00 | 27,643 | D Explanation of Responses: 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.03, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. 3. 1/12 of the original number of shares subject to this option vested and became exercisable on October 15, 2017 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter. 4. 1/12 of the original number of shares subject to this option vested and became exercisable on December 26, 2018 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter. Remarks: /s/ Henry Ji, Ph.D., as Attorney-in-Fact | 09/28/2021 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_SRNE_4_filed2021-09-28_0001209191-21-057957.xml
- Size
- 19,716 bytes
- SHA-256
- 4483e78ad78fae8c4c2f86e5d57a20081a622eed06595209ba23d6ac92a5ba29
- Original
- www.sec.gov